Tag Archives: Pharmaceutical drug

Europe: Resisting the Anticompetitive Crusade

By Julian Upton | Published: July 23, 2010
It’s been another rocky few weeks for pharma in Europe. Particularly for big brand name companies. But necessity is proving the mother of invention, says Pharm Exec’s Brussels correspondent, Reflector. AstraZeneca suffered a serious setback at the start of July when the European General Court ruled that it had illegally prevented generic competition. The case dates [...]
Posted in Strategy | Also tagged , , , , , , | Leave a comment

GSK Scores High in Market Access

By George Koroneos | Published: June 23, 2010
GlaxoSmithKline ranked number one in a study of pharmaceutical companies offering access to medicines to emerging and developing nations, proving that the UK drug giant has a far stronger grasp on new markets than its US and Japanese counterparts. The study ranks 20 companies based on significant criteria including pricing, patents and intellectual properties, capacity enhancement, [...]
Posted in Emerging Markets, Strategy | Also tagged , , , , , , | Leave a comment

Industry and FDA Brace for Change

By George Koroneos | Published: June 16, 2010
While the convention floor of the 46th annual meeting of the Drug Information Association bustled with the usual vendors touting the latest and greatest clinical trial technology, the panels (particularly those that featured FDA members) had a remarkably somber tone. The main refrain was: “Things are going to change and everyone must step up or get [...]
Posted in Regulatory, Strategy | Also tagged , , , , , | 1 Comment

Takeda Launches New Plan, Cuts US Jobs

By George Koroneos | Published: May 13, 2010
Image via Wikipedia The Japanese are taking a play from the US pharmaceutical industry’s rulebook and restructuring itself under the auspices of a fun catch phrase: “Transformation for a New Takeda.” The punch line, however, isn’t too funny. According to a two-year mid-range plan announced yesterday, Takeda will cut about 1,400 positions in the US to fend off [...]
Posted in Strategy | Also tagged , , , , , , , | Leave a comment

BIO Convention: Potemkin Pavilions and the Power of NICE

By William Looney | Published: May 11, 2010
Image by Getty Images via Daylife Last week’s annual meeting of BIO in Chicago once again proved illustrative in showcasing the high profile that governments now plays as the biotech sector’s chief advocate. While private venture capitalists confined themselves to the margins of the meeting, the Convention hall was bursting at the seams with host [...]
Posted in Biotech | Also tagged , , , , , , | Leave a comment